Sun Pharmaceutical Industries has announced a nationwide recall of
nimodipine capsules 30 mg due to crystallisation of the fill material. The
product is being manufactured by Maryland, US based Pharmaceutics
International, Inc for Sun Pharmaceutical Industries and marketed in the US by
Caraco Pharmaceutical Laboratories.
According to the company, the revenue loss on account of the same would be
negligible. The company has already commenced the recall as a
precautionary measure due to the presence of crystals of nimodipine within the
capsule solution of this lot as identified by a customer complaint. No adverse
events have been reported at this point of time.

Option contracts can be used by traders to successfully hedge against future price risk. Also risk is less as loss in case happens then only the premium amount which has been paid at the time of beginning of contract is lost.